Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

N/A

4(66.7%)

Phase 4

2(33.3%)

6Total

N/A(4)

Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT06999590Phase 4Recruiting

Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Matched Standard of Care Controls in the Management of Nonhealing Pressure Ulcers

Role: lead

NCT06826339Phase 4Recruiting

Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot and Venous Leg Ulcers.

Role: lead

NCT00905645Not ApplicableCompleted

Sientra Sponsored Silimed Gel-Filled Breast Implant Core Clinical Study

Role: lead

NCT06169670Not ApplicableUnknown

Autologous Fat Grafting to the Face With Use of the Viality™ System

Role: lead

NCT05258305Not ApplicableUnknown

AuraClens™ System in Processing of Lipoaspirate for Autologous Fat Grafting to the Breast

Role: lead

NCT02905617Terminated

Post Market Clinical Experience Study of Sientra 207 Breast Implants